Fig.3.

Working model depicting the role that the 5-Lipoxygenase plays in the development of tau neuropathology. 5LO activation promotes tau phosphorylation via the CDK5 kinase and results in neuroinflammation, memory and synaptic dysfunction. Pharmacological inhibition of 5LO enzyme activity by zileuton by preventing activation of the CDK5 kinase reduces tau phosphorylation, synaptic dysfunction, neuroinflammation, neuronal loss and ultimately disease onset.